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Abstract 22 
Context: Subclinical hypercortisolism (SH) occurs in 5-30% of adrenal incidentalomas (AIs). Common 23 
screening tests for adrenocorticotropin (ACTH)-independent hypercortisolism have significant false 24 
positive rates, mandating further time and resource intensive investigations.  25 
Objective: To determine whether low basal dehydroepiandrosterone sulphate (DHEAS) is a sensitive 26 
and specific screening test for SH in AI. 27 
Setting and Patients: 185 patients with AI were screened for adrenal medullary (plasma 28 
metanephrines) and cortical [1 mg overnight dexamethasone suppression test (ONDST), 24h urinary 29 
free cortisol (UFC), serum DHEAS, plasma renin and aldosterone] hyperfunction. Positive ONDST 30 
[≥1.8 mcg/dL (≥50 nmol/L)] and/or UFC (>upper limit of reference range) results were further 31 
investigated. We diagnosed SH when at least two of the following were met: raised UFC, raised 32 
midnight serum cortisol, 48h DST cortisol ≥1.8 mcg/dL (≥50 nmol/L).  33 
Results: Twenty-nine patients (16%) were diagnosed with SH. ACTH was <10 pg/mL (<2.2 pmol/L) 34 
in all patients with SH. We calculated age- and gender-specific DHEAS ratios (derived by dividing the 35 
DHEAS by the lower limit of the respective reference range) for all patients. ROC analyses, 36 
demonstrated that a ratio of 1.12 was sensitive (>99%) and specific (91.9%) for the diagnosis of SH. 37 
Cortisol following 1mg ONDST of 1.9 mcg/dL (53 nmol/L) was a sensitive (>99%) screening test for 38 
SH, but had lower specificity (82.9%). 24 h UFC lacked sensitivity (69%) and specificity (72%). 39 
Conclusion: A single basal measurement of DHEAS offers comparable sensitivity and greater 40 
specificity to the existing gold-standard 1 mg DST for the detection of SH in patients with AIs.  41 
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Introduction 42 
Incidentally discovered adrenal lesions [so-called adrenal incidentalomas (AIs)] are a common cause 43 
of endocrine referral (1). Although most are benign and not associated with overt endocrine 44 
dysfunction, subtler forms of adrenal hypersecretion (hypercortisolism, hyperaldosteronism, sex-45 
steroid excess or phaeochromocytoma) have been variably reported in up to 20−40 % of AIs (2,3). The 46 
terms subacute autonomous glucocorticoid hypersecretion (SAGH), subclinical Cushing’s syndrome 47 
(SCS), (possible) autonomous cortisol secretion, and subclinical hypercortisolism (SH) are often 48 
interchangeably used to denote adrenocorticotropin (ACTH)-independent cortisol secretion from a 49 
benign adrenal adenoma or nodular adrenal hyperplasia that is not associated with clinically-overt 50 
hypercortisolism (2,4,5). Several groups have reported adverse clinical sequelae in individuals with SH, 51 
with recent studies highlighting an increase in cardiovascular morbidity and mortality compared to the 52 
general population (6-12). While independent medical treatment of cardiovascular risk factors may 53 
represent a reasonable long-term management strategy for individuals with SH, recent advances in 54 
laparoscopic and retroperitonoscopic adrenalectomy raise the possibility of a potentially curative 55 
intervention for a subgroup of patients (13,14). A related, but frequently under-appreciated risk in these 56 
patients is chronic hypothalamic-pituitary-adrenal axis suppression, resulting in an impaired or absent 57 
stress response to intercurrent illness (7). Accurate exclusion or confirmation of a diagnosis of SH is 58 
therefore a key step in the investigation and management of patients with AIs.  59 
The 1 mg (overnight) dexamethasone suppression test (ONDST) is often employed as a sensitive 60 
screening test to exclude SH (1,4,15), but its relatively poor specificity (70–80%) results in a significant 61 
number of false positive tests, requiring further evaluation that is both time and resource intensive (4). 62 
This has led some workers to propose a higher threshold [≥5mcg/dL (≥138 nmol/L)] for triggering 63 
additional screening/confirmatory investigations in the context of AI (15), but with the inevitable 64 
consequence of failing to diagnose milder cases of SH. Measurement of 24 h urinary free cortisol 65 
excretion rates (UFCs) is also potentially problematic with causes of both false positive (e.g. obesity) 66 
and false negative (e.g. mild hypercortisolism, renal impairment) results recognised (4,16). 67 
Demonstration of the loss of the normal circadian rhythm of cortisol secretion is considered a sensitive 68 
 4 
test for the detection of hypercortisolism, but opinions vary as to the thresholds that should be employed 69 
to optimize detection while minimizing false positive results (for example, although a sleeping midnight 70 
serum cortisol of <1.8 mcg/dL (<50 nmol/L) effectively excludes Cushing’s syndrome in the absence 71 
of cyclical hypercortisolism, false positive results are common, especially in patients hospitalized for 72 
short periods (<48h) (4,17-19). Similarly, late night salivary cortisol is sensitive for the detection of 73 
hypercortisolism, but may be falsely elevated in shift workers, smokers or if there is blood 74 
contamination of the sample (4,20,21).  Early morning (9 AM) plasma ACTH levels are typically low 75 
or suppressed in SH, but there is overlap with ACTH levels seen in normal individuals, reflecting its 76 
pulsatile secretion and short half-life (4,22).  77 
Synthesis and secretion of the adrenal androgen dehydroepiandrosterone (DHEA), and its sulphated 78 
form DHEAS, are regulated by pituitary ACTH. Sustained suppression of central ACTH drive therefore 79 
leads to a reduction in DHEA and DHEAS levels (23-25). However, DHEA has a short half-life (25 80 
mins) and is secreted in a circadian manner similar to ACTH; hence, the interpretation of a single DHEA 81 
measurement is subject to the same caveats as with ACTH. In contrast, DHEAS has a prolonged half-82 
life in serum (10−16h), with relatively stable levels throughout the day, making it a more attractive 83 
marker for the detection of chronically suppressed ACTH. (26,27). Indeed, the potential utility of 84 
DHEAS to reflect ambient ACTH levels over a longer time interval has led to DHEAS being proposed 85 
as an indicator of persisting autonomous ACTH secretion in Cushing’s disease following pituitary 86 
surgery (28), and as a possible marker of SH in patients with AI (29, 30, 31). 87 
We therefore performed a systematic comparison of a single DHEAS measurement at presentation with 88 
the current gold-standard 1 mg dexamethasone suppression test, for the detection of SH in 185 89 
consecutive individuals with AI referred to the endocrine department of a university hospital. We 90 
describe the utility of DHEAS as a sensitive and specific marker of SH within this cohort.91 
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Patients and Methodology 92 
Patients 93 
The records of 185 consecutive patients with adrenal incidentalomas referred to the Endocrine 94 
Department of Cambridge University Hospitals Foundation Trust between January 2006 and April 2013 95 
were reviewed. All patients had undergone standardized clinical, biochemical and radiological 96 
assessments according to an Institutional protocol, as part of routine clinical care. We performed a 97 
retrospective analysis of this systematically collected dataset. Appropriate Institutional approval was 98 
obtained. 99 
Seventeen patients were excluded on the basis of: (i) concomitant use of drugs influencing 100 
glucocorticoid metabolism or secretion; (ii) major psychiatric illness or history of excess alcohol intake; 101 
or (iii) overt clinical features of hypercortisolism. One patient had previously undergone pituitary 102 
surgery and was also excluded. All AIs were discovered by computed tomography (CT) scanning or 103 
magnetic resonance imaging (MRI) performed for unrelated reasons, and all lesions were >1cm in 104 
diameter. Adrenal adenomas displayed the following radiological features: either ≤10 HU on 105 
unenhanced CT (in which case no further characterization was performed); or >50% absolute washout 106 
at 10 minutes (or >60% at 15 minutes) on triple phase adrenal CT; or signal dropout on chemical shift 107 
MRI (32,33).  108 
All patients were assessed by one of three clinicians experienced in the diagnosis and management of 109 
Cushing’s syndrome, and each underwent standardized clinical and biochemical screening at first 110 
presentation according to an institutional clinical protocol. This included measurement of plasma 111 
metanephrines, 24 h urine collection for urinary free cortisol estimation (UFC), plasma renin and 112 
aldosterone, serum DHEAS, electrolytes, liver blood tests, fasting plasma glucose, fasting lipids and 113 
complete blood count. All patients also underwent a 1 mg overnight dexamethasone suppression test, 114 
with values <1.8 mcg/dL (<50nmol/L) signifying adequate suppression (34). Measurement of UFC was 115 
performed separately on two 24 h urine collections, with the higher of the two values used for 116 
subsequent analysis. Patients returning a post-dexamethasone cortisol ≥1.8 mcg/dL (≥50 nmol/L) 117 
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and/or raised UFC [>6.5 mcg/dL (>180 nmol)/24 h prior to 2011 and >5.3 mcg/dL (>146 nmol)/24 h 118 
after 2011] underwent more detailed evaluation during an inpatient admission as follows: repeat 24 h 119 
UFC, midnight serum cortisol, 48 h low dose (0.5 mg qds) dexamethasone suppression test (LDDST), 120 
plasma ACTH (measured on 2 occasions between 08:00 and 09:00). We diagnosed SH in the presence 121 
of at least two of the following: failure to suppress serum cortisol to <1.8 mcg/dL (<50 nmol/L) 122 
following dexamethasone; sleeping midnight serum cortisol >1.8 mcg/dL (>50 nmol/L) or awake 123 
midnight serum cortisol >7.5 mcg/dL (>207 nmol/L); raised UFC (32). Although not used as a 124 
diagnostic criterion, all patients subsequently confirmed with SH had a 09:00 ACTH level <10 pg/mL 125 
(<2.2 pmol/L). All investigations were reviewed by two endocrinologists (MCD, MG), who were 126 
blinded to the DHEAS result for each patient. For the purpose of analyses, a DHEAS ratio was 127 
calculated by dividing the measured DHEAS by the lower limit of the respective reference range (age- 128 
and sex-matched). DHEAS values reported as falling below the lower limit of detection of the assay 129 
[<15.0 mcg/dL (<0.4 micromol/L)] were interpreted as equivalent to the lowest measurable value [i.e. 130 
15.0 mcg/dL (0.4 micromol/L)]. 131 
Assays 132 
Biochemical assays were run in a UKAS (http://www.ukas.com/default.asp) accredited clinical 133 
laboratory. External Quality Assurance (EQA) for all assays was provided by UKNEQAS 134 
(http://www.ukneqas.org.uk).  135 
DHEAS and ACTH were assayed using a Siemens (Surrey, UK) Immulite 2000 platform with reagents 136 
provided by the same manufacturer. DHEAS was analyzed by solid phase competitive immunoassay. 137 
Age and sex adjusted reference ranges for DHEAS are provided in Table 1. ACTH was analysed by 138 
sequential two site solid phase chemiluminescent immunoassay.  139 
Aldosterone was measured using solid phase radioimmunoassay (Coat-A-Count, Siemens, Los 140 
Angeles, USA). The Laboratory working range was 70–3330 pmol/L. Plasma Renin was measured 141 
using a Diasorin XL (Kent, UK) chemillumunescent immunometric assay. The Laboratory working 142 
range was 2–3000 μIU/mL. 143 
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Plasma metanephrines were analyzed using a derivitization ELISA assay provided by Labor 144 
Diagnosticka Nord GmbH (Nordhorn, Germany). The Laboratory working range was 41-2100 pg/mL 145 
for metanephrine and 58-58000 pg/mL for normetanephrine.  146 
Urine cortisol was measured by competitive radioimmunoassay using reagents provided by Siemens 147 
(Coat-a-Count) or using an in-house liquid chromatography – tandem mass spectrometry method. The 148 
Laboratory working range was 25-1380 nmol/L and the laboratory reference range for the RIA was 149 
<180 nmol/24 h. The mass spectrometric assay was performed using an API 5500 triple quadrupole 150 
mass spectrometer (ABPsiex, UK) using atmospheric pressure chemical ionization.  Deuterated (d4) 151 
cortisol was used as an internal standard. Urine samples were mixed with internal standard in 50% 152 
methanol/water.  Samples were pre-cleaned using a C8 reverse phase column before HPLC separation 153 
using a pheny-hex column with a shimadzu HPLC system. The Laboratory working range was 12–2330 154 
nmol/L and the laboratory reference interval for the liquid chromatography–tandem mass spectrometry 155 
method was <146 nmol/24 h. 156 
Between batch imprecision was <10% across the working ranges for all assays. 157 
 158 
Statistical Analysis 159 
With the exception of age and body mass index, which are reported as mean ± standard deviation (SD), 160 
all data are expressed as medians with interquartile ranges. For parametric data, hypothesis testing was 161 
performed using an unpaired students t-test. For non-parametric data, statistical analysis was performed 162 
using the Mann Whitney U Test.  163 
Receiver operated characteristic (ROC) curves were generated to assess the utility of DHEAS in the 164 
diagnosis of SH, using the first, randomly sampled DHEAS ratio for each patient included in the study.  165 
ROC curves were also generated for the 1 mg overnight dexamethasone suppression test and the original 166 
24 h UFC measurement.  167 
ROC analysis evaluated the performance of each parameter for the diagnosis of SH against non-168 
functioning adrenal adenomas (NFAs). Performance of each screening / diagnostic test is expressed as 169 
 8 
area under the curve (AUC) with 95% confidence intervals. Data are also presented for sensitivity and 170 
specificity for each screening / diagnostic test with 95% confidence intervals. All analyses were 171 
performed using SPSS V 21.0 or GraphPad Prism V 6.0. 172 
Due to the systematic nature of investigation for AI in our Institution, and robust data collection, there 173 
were no missing data for ONDST, LDDST, UFC or demographic details in the study cohort.  174 
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Results 175 
Patient Characteristics 176 
As described above, 18 subjects were excluded from further analyses due to confounding clinical 177 
disorders or medication usage. Final diagnoses in the remaining 167 patients were: non-functioning 178 
adrenal adenoma (n=97), subclinical hypercortisolism (n=29), phaeochromocytoma (n=19), adrenal 179 
metastasis (n=8), primary aldosteronism (n=4), adrenal hemorrhage (n=2), adrenocortical carcinoma 180 
(n=2), myelolipoma (n=2), oncocytoma (n=1) and three subjects had Cushing’s disease with an adrenal 181 
incidentaloma (Supplemental Fig. 1A). There was no difference in age [NFA: 63.4 ± 12.8 yr (mean ± 182 
SD); SH: 65.8 ± 11.3 yr (p=0.36)], sex [NFA: Male 44/97; SH: Male 14/29 (p=0.41)] or body mass 183 
index [NFA: 31.8 ± 9.2 kg/m2 (mean ± SD); SH: 29.4 ± 7.5 kg/m2 (p=0.91)] between the NFA and SH 184 
subgroups. The age distribution of the cohort as a whole was consistent with other published series 185 
(Supplemental Fig. 1B) (6-11). Twenty-three patients had bilateral adrenal adenomas (16 NFA; 7 SH). 186 
DHEAS ratio for the screening and diagnosis of SH 187 
There was a significant difference in the DHEAS ratio between the two study groups [median 2.62 (1.8, 188 
5.5) for NFAs versus 1.0 (0.77, 1.0) for SH; p < 0.0001]. DHEAS ratio was a sensitive and specific test 189 
both with respect to screening and diagnosis of SH versus NFA [AUC 0.95 (0.91, 0.99); p<0.0001]. 190 
Evaluation for SH versus NFA showed that for a DHEAS ratio of 1.12, sensitivity was 100% (86.2, 191 
100) and specificity was 91.9% (83.9, 96.7) (Fig. 1). This finding was consistent in a subgroup analysis 192 
of patients with bilateral adrenal adenomas (Supplemental Fig. 2A). In fact, DHEAS ratio also 193 
performed well as a sensitive and a specific test for the diagnosis of SH against all other causes of 194 
adrenal lesions within this cohort, as all other non-SH causes of adrenal nodules returned a DHEAS 195 
ratio >1.12. Included in this, a low DHEAS ratio also differentiated between ACTH-independent and 196 
ACTH-dependent hypercortisolemia in the presence of an adrenal lesion (Supplemental Fig. 3). 197 
1 mg dexamethasone suppression test for the screening and diagnosis of SH 198 
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There was a significant difference between the two study groups with respect to post-1mg 199 
dexamethasone cortisol levels: median 1.3 mcg/dL (0.91, 1.71) [36 nmol/L (25.0, 47.3)] for NFAs, 200 
versus 4.2 mcg/dL (1.96, 8.73) [116 nmol/L (92.0, 241.0)] for SH (p<0.0001). As expected, the 1 mg 201 
overnight dexamethasone suppression test performed well as a screening test for SH when compared 202 
with NFAs [AUC 0.97 (0.95, 0.99); p<0.0001] (Fig. 2). A post-dexamethasone value of 1.9 mcg/dL (53 203 
nmol/L) yielded a sensitivity >99% (87.2, 100) and a specificity of 82.9% (73.4, 90.1). As a diagnostic 204 
test, a value of 4.0 mcg/dL (109 nmol/L) had a sensitivity of 55.5% (35.3, 74.5) with a specificity of 205 
>99% (95.9, 100). A post-dexamethasone cortisol of 2.1 mcg/dL (58.5 nmol/L) gave the best overall 206 
test performance: sensitivity 92.5% (75.7, 99.0); specificity 88.6% (80.1, 94.4). Findings in those with 207 
bilateral adrenal adenomas were largely consistent with this (Supplemental Fig. 2B). The 1 mg 208 
overnight dexamethasone suppression test did not differentiate between SH and other causes of 209 
hypercortisolism such as ACTH-mediated or adrenocortical carcinoma.  210 
24 hour UFC for the screening and diagnosis of SH 211 
For the purpose of analyses, a UFC ratio was calculated by dividing the measured 24 hour UFC by the 212 
upper limit of the reference range. There was a significant difference in the UFC ratio between the two 213 
study groups: median 0.74 (0.46, 1.16) for NFAs versus 1.3 (0.95, 1.84) for SH (p < 0.0001) (Fig. 3). 214 
However, UFC performed relatively poorly both as a screening test and as a diagnostic test for SH 215 
versus NFA [AUC 0.77 (0.67, 0.87); p<0.01], and this pattern held true for bilateral adenomas 216 
(Supplemental Fig 2C). A ratio of 1.01 gave a sensitivity of 69 % (48.2, 85.7) and a specificity of 67% 217 
(55.5, 78.2). A ratio of 0.47 gave a sensitivity of 100% (86.8, 100) but a specificity of 25.3% (15.8, 218 
37.1), while a ratio of 2.1 gave a specificity of 100% (94.9, 100), but a sensitivity of just 19.2% (6.6, 219 
39.4). Therefore, while UFC did not perform well as a screening test, a value greater than twice the 220 
upper limit of the reference range performed well as a confirmatory test (Fig. 3).   221 
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Discussion 222 
In this study we have robustly evaluated the diagnostic utility of a single DHEAS measurement as a 223 
sensitive and specific marker of SH in adrenal incidentalomas, using a complete and systematically 224 
collected dataset. Consecutive patients referred to our service were investigated using widely accepted 225 
screening and confirmatory tests (4). For every patient we also calculated a ratio of measured DHEAS 226 
to the age- and sex-specific lower reference interval. Using this approach, DHEAS ratio performed well 227 
as a screening test for SH, with a threshold of ≤1.12 demonstrating a sensitivity >99% while showing 228 
higher specificity than the ONDST (91% versus 86% respectively) (Figs. 1 & 2). Moreover, DHEAS 229 
ratio reliably differentiated between SH and non-SH etiologies of adrenal nodules within our cohort 230 
(Supplemental Fig. 3).  231 
Our findings lend important support to previous proposals and guidelines, which have observed that  a 232 
low or suppressed DHEAS level should be considered a potential  indicator of SH in the context of AI 233 
(29-31). Yener and colleagues have also explored the association between low DHEAS levels and SH, 234 
noting that an age-unadjusted DHEAS threshold of 40.0 mcg/dL provided a sensitivity of 68% and 235 
specificity of 75% for the diagnosis of SH (29). In the study reported here, we have demonstrated a 236 
higher sensitivity and specificity for low DHEAS in the diagnosis of SH. This may be explained by 237 
some important differences in study design. Firstly, rather than adopting a higher ONDST threshold 238 
[3.0 mcg/dL (83 nmol/L)] as a confirmatory test for SH, we have used the diagnostic criteria 239 
recommended in the Endocrine Society Clinical Practice Guidelines (4), which include the LDDST as 240 
a ‘gold standard’ confirmatory test. In our hands, when compared with the LDDST, the higher ONDST 241 
threshold of 3.0 mcg/dL (83 nmol/L) performed less well as a confirmatory test for SH, returning a 242 
sensitivity of 85% and specificity of 95%. Secondly, we have accounted for the expected age-related 243 
decline and sex-related differences in DHEAS by calculating a sex- and age-adjusted DHEAS ratio 244 
based on locally validated reference ranges, rather than using absolute DHEAS values (Table 1). 245 
Although a previous report by Bencsik and colleagues suggested that DHEAS may not be a useful 246 
indicator of hormonal activity in AI (34), the main focus of this study was to explore the potential for 247 
DHEAS to discriminate benign from malignant AI. Moreover, the analysis was restricted to only a 248 
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small number of histologically-confirmed cases (thus introducing potential selection bias). Importantly 249 
the authors noted that DHEAS measurement may have a role once the cortical origin and benign feature 250 
of the tumor has been confirmed. 251 
In this study we employed robust criteria for the diagnosis of SH across multiple testing modalities, 252 
which allowed us to also examine the performance of investigations that are commonly used to 253 
detect/exclude hypercortisolism. The ONDST performed well as a screening test for SH. The traditional 254 
cortisol threshold of ≥1.8 mcg/dL (≥50 nmol/L) yielded a sensitivity >99% and a specificity of 81%, 255 
consistent with previous findings for this test (Fig. 2) (4) . The higher suggested cut-off value for cortisol 256 
of ≥5 mcg/dL (>138 nmol/L) post-dexamethasone provided a specific test (>99%), but at the cost of a 257 
low sensitivity of 41% which would have missed the majority of subsequently diagnosed SH within 258 
this cohort. In our hands the lowest cut-off cortisol value which produced a specificity >99% was 109 259 
nmol/L. However, this was associated with lower sensitivity (56%) and hence performed poorly as a 260 
screening test. As anticipated, the ONDST did not differentiate between ACTH-dependent and 261 
independent forms of hypercortisolaemia. Accordingly, we support the traditional cortisol threshold of 262 
≥1.8 mcg/dL (≥50 nmol/L) in the ONDST as the trigger for further confirmatory testing as 263 
recommended in the Endocrine Society and European Society guidelines (4).  264 
The utility of urinary free cortisol in the diagnosis of SH and in the broader context of Cushing’s 265 
syndrome has long been debated. There are numerous pitfalls associated with this test. Urine collection 266 
over a 24 h period is not always convenient for the patient and it is often difficult to obtain a complete 267 
sample in the clinic setting. Several studies have shown that 24 h UFC measurement performs poorly 268 
overall both as a screening and a diagnostic test, particularly if reliance is placed on a single 269 
measurement (20). Within our cohort 24 h UFC (measured on two occasions with the highest value 270 
used for subsequent analyses) demonstrated a low sensitivity (67%) and specificity (69%), although 271 
values ≥ 2 times the upper limit of the reference range carried a specificity >99% but a sensitivity of 272 
only 25% (Fig. 3). It is important to note however, that we used a univariate UFC measurement, rather 273 
than the multi-analyte, steroid metabolomic profiling that is increasingly available, with more recent 274 
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data suggesting superior sensitivity and specificity of urinary steroid metabolomics for the differential 275 
diagnosis of steroid excess in the context of adrenal disease (35). 276 
In the setting of SH, ACTH levels are typically suppressed and we also observed this, with all affected 277 
patients returning levels <10 ng/L (<2.2 pmol/L). However, measurement of ACTH in the clinical 278 
setting carries multiple sampling challenges and can produce false positive results when sampled under 279 
non-ideal circumstances, reflecting the short half-life, pulsatile secretion and diurnal variability of 280 
ACTH release (4). 281 
Measurement of DHEAS also offers some other potential advantages when screening in AI: firstly, it 282 
allows detection of tumors that are co-secretory (and therefore suspicious for malignancy); secondly, it 283 
has recently been recognized that some cases of congenital adrenal hyperplasia may present with AI, 284 
although we did not identify any such cases in our cohort (36). 285 
It is important to note however that the reliability of low or suppressed DHEAS as a marker for SH test 286 
may be limited under certain circumstances, for example when there is pre-existing ACTH-suppression 287 
in the context of chronic glucocorticoid or opioid use, pituitary disease or hypothalamic dysfunction. 288 
Under these circumstances a false positive result may be obtained (37). However, each of the existing 289 
screening tests have well recognized limitations and pitfalls, and also require specific sampling 290 
conditions.  291 
Our study has other potential limitations. The reported data are representative of a patient population 292 
attending a single center, using a single platform for DHEAS measurement. Multi-center studies and/or 293 
meta-analyses, specifically investigating the use of the DHEAS ratio reported here as a screening test 294 
for SH in the context of AI will be required to support and validate our findings, across patient 295 
populations, using different DHEAS assays. It will also be important to validate the utility of DHEAS 296 
ratio alone or in combination with the ONDST (at differing threshold values) for confirming or 297 
excluding SH without the need to progress to more expensive, time-consuming investigations. 298 
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Finally, low DHEAS has also been directly linked with increased cardiovascular risk (38), and it is 299 
interesting to speculate that undiagnosed SH may underlie this association given the recent 300 
demonstration that SH is associated with excess cardiovascular mortality (7,10,39). 301 
In conclusion, our data support the use of an age-adjusted DHEAS ratio as a sensitive and specific 302 
screening test for SH in patients with incidentally detected adrenal incidentalomas. Pending further 303 
studies, we suggest that the identification of a low or suppressed DHEAS level in a patient with AI 304 
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